Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: A real-world experience

Theodor Bilharz Research Institute

Bibliographic Information

Authors: El-Khayat H.R.; Fouad Y.M.; Maher M.; El-Amin H.; Muhammed H.

Journal: Gut

Publisher: BMJ Publishing Group

Publication Date: 10 August 2016

Volume / Issue: Volume 66 / Issue 11

Pages: 2008–2012

ISSN: 175749

DOI: 10.1136/gutjnl-2016-312012

Scopus: View on Scopus

PubMed: 27511197

Document Type: Article


Authors and Affiliations

El-Khayat H.R., Gastroenterology and Endemic Medicine Department, Theodore Research Institute, Cairo, Egypt; Fouad Y.M., Gastroenterology and Endemic Medicine Department, Minia University, Minia, 19111, Egypt; Maher M., Gastroenterology and Endemic Medicine Department, Ain Shams University, Cairo, Egypt; El-Amin H., Internal Medicine Department, Assuit University, Assuit, Egypt; Muhammed H., Gastroenterology and Endemic Medicine, Endemic Medicine Department, Minia University, Minia, Egypt


Abstract

Background Simeprevir plus sofosbuvir (SIM/SOF) regimen was recommended by professional guidelines for certain patients with HCV genotype 1 infection and there is lack of data about this regimen in patients with genotype 4 infection. Aim To evaluate the efficacy and safety of this regimen in Egyptian patients with chronic HCV genotype 4 infection in the real world. Methods Multicentre observational study included 583 patients with HCV genotype 4 infection who began 12â €..weeks of treatment with SIM plus SOF. Demographic, clinical and virological data as well as adverse outcomes were collected. Treatment naïve patients were 342 (59%) of all included patients, 45% of patients had severe fibrosis (F3 and F4) while 55% had mild fibrosis (F1 and F2) and the primary outcome was sustained virological response (SVR). Results The overall SVR rate was 95.7% (558 out of 583 patients). In total, SVR12 in naïve patients with mild fibrosis score (F1 and F2) was achieved in 98.9% (94/95) for F1 and 98.1% (105/107) for F2, while naïve patients with severe fibrosis (F3 and F4) achieved SVR of 97.7% (86/88) for F3 and (42/52) 80.8% for F4. SVR in patients with previous interferon treatment achieved in 100% (45/45) for patients with F1 and 98.7% (74/75) for F2. While 94.7% (72/76) in experienced patients with F3; and 88.9% (40/45) for F4 achieved SVR12. Notable side effects included rash in 21 patients, photosensitivity in 18 patients, pruritus in 44 patients and hyperbilirubinemia in 42 patients. Conclusions A 12-week regimen of simeprevir/sofosbuvir was efficacious and well tolerated by treatment-naïve and treatment-experienced patients with chronic HCV genotype 4. © Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-And-licensing/.


Keywords

CHRONIC HEPATITIS; CIRRHOSIS; HCV; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult; interferon; antivirus agent; Article; chronic hepatitis C; cohort analysis; demography; disease severity; drug efficacy; drug safety; Egyptian; gastrointestinal hemorrhage; hepatic encephalopathy; Hepatitis C virus genotype 1; Hepatitis C virus genotype 4; human; hyperbilirubinemia; liver fibrosis; major clinical study; multicenter study; observational study; photosensitivity; priority journal; pruritus; rash; scoring system; side effect; sustained virologic response; thrombocytopenia; treatment duration; clinical trial; combination drug therapy; drug administration; follow up; genetics; very elderly; virology


Citation Information

Scopus Citations: 25


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects